NCOA3 has been found to be elevated in breast cancer, liver cancer, prostate cancer, and colorectal cancer, correlated with poor prognosis in most cases, and a vital regulator in the process of tumorigenesis, progression, metastasis, and survival (Anzick et al., 1997; Chen et al., 2012; Shi et al., 2015; Xie et al., 2005; Xu et al., 2010; Zhou et al., 2005). Here, NCOA3 is linked to colorectal cancer.